Nonsyndromic cleft lip with or without cleft palate and cancer: Evaluation of a possible common genetic background through the analysis of GWAS data

Eva Dunkhase a, Kerstin U. Ludwig a,b, Michael Knapp c, Christine F. Skibola d, Jane C. Figueiredo e, Fay Julie Hosking f, Eva Ellinghaus g, Maria Teresa Landi h, Hongxia Ma i, Hidewaki Nakagawa j, Jong-Won Kim k, Jiali Han l, Ping Yang m, Anne C. Böhmer a,b, Manuel Mattheisen a,b,c, Markus M. Nöthen a,b, Elisabeth Mangold a,x

a Institute of Human Genetics, University of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany
b Department of Genomics, Life and Brain Center, University of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany
c Institute of Medical Biometry, Informatics, and Epidemiology, University of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany
d Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, AL 35294, USA
e Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA
f Division of Genomics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, Surrey, UK
g Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Schittenhelmstr. 12, 24105 Kiel, Germany
h Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, (06351) 81 Irwon-Ro Gangnam-gu, Seoul, Republic of Korea
i National Cancer Institute, NIH, DHHS, 9609 Medical Center Dr, Rockville, MD 20850, USA
j Department of Epidemiology, School of Public Health, Nanjing Medical University, 140 Hanzhong Rd, Gulou, Nanjing 210029, Jiangsu, China
k Laboratory for Genome Sequencing Analysis, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 220-0045, Japan
l Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, (06351) 81 Irwon-Ro Gangnam-gu, Seoul, Republic of Korea
m Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin & Bren Simon Cancer Center, Indiana University, 535 Barnhill Dr, Indianapolis, IN 46202, USA
n Mayo Clinic, 200 First St. SW Rochester, MN 55905, USA

A R T I C L E   I N F O

Keywords:
Cleft lip
Cleft palate
Genome-wide association study
Single nucleotide polymorphism
Cancer

A B S T R A C T

Previous research suggests a genetic overlap between nonsyndromic cleft lip with or without cleft palate (NSCL/P) and cancer. The aim of the present study was to identify common genetic risk loci for NSCL/P and cancer entities that have been reported to co-occur with orofacial clefting. This was achieved through the investigation of large genome-wide association study datasets. Investigations of 12 NSCL/P single nucleotide polymorphisms (SNPs) in 32 cancer datasets, and 204 cancer SNPs in two NSCL/P datasets, were performed. The SNPs rs13041247 (20q12) and rs6457327 (6p21.33) showed suggestive evidence for an association with both NSCL/P and cancer subtypes. One of the largest investigations to date is the Danish registry cohort study of Bille et al. [4]. The authors found a significantly higher prevalence of: breast cancer in females with cleft lip and/or cleft palate; brain cancer in females with cleft palate; and lung cancer in males with cleft lip and palate. Further studies have supported an association [13, 43,47,72], whereas others have not [6,8,56]. As both cancer and OFC have a multifactorial etiology, shared risk factors might be genetic, environmental, or a combination of both. Molecular studies - in particular recent GWAS - have identified susceptibility factors for various cancer subtypes [14]. The first GWAS of cancer in the late 2000s reported a limited number of loci for the most common cancer cases in order to determine the prevalence of co-morbid congenital abnormalities. Miller reported associations between Down's syndrome and leukemia, and aniridia and Wilms' tumor. Various epidemiological study designs have since been applied to identify associations between specific cancer entities and OFC or particular clefting subtypes. One of the largest investigations to date is the Danish registry cohort study of Bille et al. [4]. The authors found a significantly higher prevalence of: breast cancer in females with cleft lip and/or cleft palate; brain cancer in females with cleft palate; and lung cancer in males with cleft lip and palate. Further studies have supported an association [13, 43,47,72], whereas others have not [6,8,56].

1. Introduction

Orofacial clefting (OFC) is a common congenital malformation comprising several subtypes. The most frequent form is nonsyndromic ‘cleft lip with or without cleft palate’ (NSCL/P), which is characterized by clefting of the upper lip and facultative clefting of the palate [46]. NSCL/P etiology involves both environmental and genetic factors. Genome-wide association studies (GWAS) have provided insights into the genetic background of NSCL/P through the identification of several risk loci [40,42].

Research suggests a common genetic etiology for congenital malformations - including OFC - and specific cancer entities. Miller [45] analyzed the death certificates of approximately 30,000 pediatric cancer cases in order to determine the prevalence of co-morbid congenital abnormalities. Miller reported associations between Down’s syndrome and leukemia, and aniridia and Wilms’ tumor. Various epidemiological study designs have since been applied to identify associations between specific cancer entities and OFC or particular clefting subtypes. One of the largest investigations to date is the Danish registry cohort study of Bille et al. [4]. The authors found a significantly higher prevalence of: breast cancer in females with cleft lip and/or cleft palate; brain cancer in females with cleft palate; and lung cancer in males with cleft lip and palate. Further studies have supported an association [13, 43,47,72], whereas others have not [6,8,56].

As both cancer and OFC have a multifactorial etiology, shared risk factors might be genetic, environmental, or a combination of both. Molecular studies - in particular recent GWAS - have identified susceptibility factors for various cancer subtypes [14]. The first GWAS of cancer in the late 2000s reported a limited number of loci for the most common cancer cases in order to determine the prevalence of co-morbid congenital abnormalities. Miller reported associations between Down’s syndrome and leukemia, and aniridia and Wilms’ tumor. Various epidemiological study designs have since been applied to identify associations between specific cancer entities and OFC or particular clefting subtypes. One of the largest investigations to date is the Danish registry cohort study of Bille et al. [4]. The authors found a significantly higher prevalence of: breast cancer in females with cleft lip and/or cleft palate; brain cancer in females with cleft palate; and lung cancer in males with cleft lip and palate. Further studies have supported an association [13, 43,47,72], whereas others have not [6,8,56].

Corresponding author.
E-mail address: e.mangold@uni-bonn.de (E. Mangold).
malignancies. To date, individual studies and meta-analyses have identified approximately 50 susceptibility loci for colorectal cancer, >70 for breast cancer, and >100 for prostate cancer. Of particular interest is the finding that chromosomal region 8q24.21 contains several cancer-risk single nucleotide polymorphisms (SNPs) [25], and a major risk locus for NSCL/P [5].

The majority of published investigations into a common genetic etiology for OFC and cancer have been purely descriptive. To date, strong molecular evidence for an association between cancer and OFC has been generated for only one gene. In the respective resequencing study, a causative role for the gene CDH1 was identified in both gastric cancer and OFC [9]. A limitation of previous studies is that they were based on the analysis of candidate genes and/or particular pedigrees. To overcome this, the present study used genome-wide SNP data from large cohorts of patients with sporadic cancers or NSCL/P. Analyses were performed to identify common genetic risk loci for NSCL/P and those cancer entities for which co-occurrence with NSCL/P has been reported. The identification of shared risk loci would provide insights into common underlying mechanisms.

2. Materials and methods

2.1. Cancer entity search strategy

In a first step, a Pubmed search was performed to locate original studies published prior to July 2012 that had investigated an association between OFC and cancer. The following search terms were used: “cleft cancer”, “cleft tumor”, “cleft lip cancer”, “cleft palate cancer”, “cleft palate tumor”, “facial cleft cancer”, “facial cleft tumor”, “oral cleft cancer”, “oral cleft tumor”, “orofacial cleft cancer”, and “orofacial cleft tumor”. In the OFC literature, nomenclature is inconsistently applied and broad search terms were used in order to ensure that relevant studies were not overlooked due to the use of alternative morphological classification. The reference lists of these publications were then scrutinized to identify additional studies. On the basis of these search results, a list of cancer entities with a reported association with any form of OFC was compiled.

This list was then reduced to cancer entities with a reported association with NSCL/P. Studies that had investigated other OFC phenotypes (i.e., cleft palate only, syndromic OFC, or anomalies such as tooth agenesis and bifid uvula) were excluded. Data from case reports and animal models were also excluded from the analyses (Supplementary Table S1).

2.2. Cancer GWAS search strategy

In a second step, a search of the “NHGRI GWAS Online Catalog” ([29], http://www.genome.gov/gwastudies) was performed to identify GWAS of those cancer entities for which an association with NSCL/P had been reported (cancer entities of interest listed in Supplementary Table S1). Since this GWAS catalog is not exhaustive, the search was complemented using PubMed. The following search terms, followed by the respective cancer subtype, were used: “genome-wide association studies”, “genome-wide association study”, “gwas”, “gwa”.

2.3. Identification of NSCL/P risk SNPs from the literature

Prior to July 2012, three GWAS of NSCL/P were performed in European case-control samples [5,26,41], and one GWAS was performed in European and Asian trios [2]. Subsequently, two meta-analyses of GWAS data from Mangold et al. [41] and Beaty et al. [2] were performed [40]. In total, 12 loci in these studies showed genome-wide significance. These comprised one established NSCL/P risk locus (IRF6), and 11 novel loci. Twelve lead SNPs at these loci were chosen as NSCL/P risk SNPs for the present study (Table 1).

2.4. Identification of cancer risk SNPs from the literature

All autosomal SNPs with genome-wide significance in at least one cancer GWAS published prior to July 2012 were listed. According to the guidelines of the International HapMap Consortium [32], an SNP should be considered genome-wide significant if it achieves a P-value below a threshold of 5 × 10^-8. As an exception to this rule, the present study also included SNPs with a P-value of >5 × 10^-8 if they had been defined as genome-wide significant in the original study.

2.5. Exploration of genome-wide SNP datasets

Data on NSCL/P-associated genetic variants were retrieved from the meta-analyses of the two largest GWAS of NSCL/P to date [40]. Ludwig et al. [40] included 497,084 SNPs, which had been genotyped in 666 complete European trios, 795 complete Asian trios, and 399 patients and 1318 controls of Central European origin. This study included 95% of all individuals available at that time with both NSCL/P and genome-wide data. For SNPs in the cancer SNP list, analyses were performed to determine association with NSCL/P in the two meta-analyses: i) European (meta_Euro); and ii) the combined European/Asian population (meta_all) datasets.

Additionally, the corresponding authors of all cancer GWAS used for SNP selection were contacted. These researchers were asked to retrieve association information from their cancer GWAS datasets for each lead SNP from the 12 NSCL/P risk loci (Table 1), if available.

For both analyses, cancer and NSCL/P SNPs that were not represented in the respective analyzed data were replaced by a proxy SNP (r^2 > 0.5 in the HapMap CEU population, Supplementary methods). For the P-values of cancer-associated SNPs in the NSCL/P meta-analyses, correction for multiple testing was performed using a simulation procedure. This was based on 10,000 replicated samples, and involved permutation of: (i) the case and control status of individuals; and (ii) the transmitted and non-transmitted parental alleles.

For the analysis of NSCL/P-associated SNPs in the cancer GWAS, a correction factor of 384 was used (12 risk loci, 32 cancer GWAS datasets).

3. Results

The cancer entity search for studies that had analyzed the co-occurrence of orofacial anomalies and cancer identified 36 publications (Supplementary Table S1). Of these, 10 contained sufficient information to deduce that the described associations were with the NSCL/P phenotype. These 10 studies covered 11 different cancer entities, all of which were primary forms of cancer, i.e., they were not metastatic tumors. These cancer entities comprised: brain cancer [4,22,43]; breast cancer [4,43]; colorectal cancer [43]; leukemia [43,44,48,69,72]; liver cancer

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCL/P-associated risk SNPs identified in GWAS.</td>
</tr>
<tr>
<td>SNP-ID</td>
</tr>
<tr>
<td>rs560426</td>
</tr>
<tr>
<td>rs861020</td>
</tr>
<tr>
<td>rs742071</td>
</tr>
<tr>
<td>rs7550268</td>
</tr>
<tr>
<td>rs76532427</td>
</tr>
<tr>
<td>rs12543218</td>
</tr>
<tr>
<td>rs987525</td>
</tr>
<tr>
<td>rs7078160</td>
</tr>
<tr>
<td>rs8001641</td>
</tr>
<tr>
<td>rs1873147</td>
</tr>
<tr>
<td>rs227731</td>
</tr>
<tr>
<td>rs13041247</td>
</tr>
</tbody>
</table>

* Chr. = chromosomal.

| Minor allele first, risk allele for NSCL/P in bold. |
n/s = not specified; P_{meta_Euro} and P_{meta_all} = P-value from Likelihood ratio test in the European or European/Asian meta-analysis respectively; FL = follicular lymphoma; ALL = acute lymphoblastic leukemia; cHL = classical Hodgkin lymphoma; BCC = basal cell carcinoma.

### Table 2

<table>
<thead>
<tr>
<th>SNP-ID (risk allele in NSCL/P)</th>
<th>Proxy required?</th>
<th>Cancer entity</th>
<th>Risk</th>
<th>Ref</th>
<th>P-value</th>
<th>OR</th>
<th>OR type</th>
<th>Number of cases/controls</th>
<th>Sample ethnicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs13014247 (T)</td>
<td>†</td>
<td>skin cancer (SCC)</td>
<td>C</td>
<td>T</td>
<td>4.73 × 10^{-6}</td>
<td>1.23</td>
<td>allelic</td>
<td>973/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs13014247 (T)</td>
<td>†</td>
<td>skin cancer (BCC)</td>
<td>C</td>
<td>T</td>
<td>1.04 × 10^{-3}</td>
<td>1.10</td>
<td>allelic</td>
<td>2807/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs13014247 (T)</td>
<td>†</td>
<td>lymphoma (CL)</td>
<td>C</td>
<td>T</td>
<td>3.34 × 10^{-3}</td>
<td>1.16</td>
<td>allelic</td>
<td>725/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs13014247 (T)</td>
<td>†</td>
<td>lymphoma (CL)</td>
<td>C</td>
<td>T</td>
<td>3.31 × 10^{-3}</td>
<td>1.27</td>
<td>genotypic</td>
<td>407/296</td>
<td>EU</td>
</tr>
<tr>
<td>rs13014247 (T)</td>
<td>†</td>
<td>lymphoma (CL)</td>
<td>C</td>
<td>T</td>
<td>4.14 × 10^{-2}</td>
<td>1.25</td>
<td>allelic</td>
<td>148/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs13014247 (T)</td>
<td>†</td>
<td>brain cancer (glioma)</td>
<td>C</td>
<td>T</td>
<td>4.18 × 10^{-2}</td>
<td>1.14</td>
<td>n/s</td>
<td>846/1310</td>
<td>EU*</td>
</tr>
<tr>
<td>rs1873147 (C)</td>
<td>*</td>
<td>brain cancer (glioma)</td>
<td>A</td>
<td>G</td>
<td>4.50 × 10^{-2}</td>
<td>1.17</td>
<td>n/s</td>
<td>846/1310</td>
<td>EU*</td>
</tr>
<tr>
<td>rs227731 (C)</td>
<td>†</td>
<td>prostate cancer</td>
<td>T</td>
<td>G</td>
<td>1.40 × 10^{-3}</td>
<td>1.10</td>
<td>allelic</td>
<td>2682/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs227731 (C)</td>
<td>†</td>
<td>skin cancer (BCC)</td>
<td>T</td>
<td>G</td>
<td>2.35 × 10^{-3}</td>
<td>1.09</td>
<td>allelic</td>
<td>2807/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs227731 (C)</td>
<td>†</td>
<td>skin cancer (BCC)</td>
<td>T</td>
<td>G</td>
<td>1.83 × 10^{-2}</td>
<td>1.14</td>
<td>n/s</td>
<td>725/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs227731 (C)</td>
<td>†</td>
<td>skin cancer (BCC)</td>
<td>T</td>
<td>G</td>
<td>3.29 × 10^{-2}</td>
<td>1.08</td>
<td>allelic</td>
<td>2045/6013</td>
<td>EU</td>
</tr>
<tr>
<td>rs560426 (G)</td>
<td>*</td>
<td>prostate cancer</td>
<td>T</td>
<td>C</td>
<td>5.83 × 10^{-3}</td>
<td>1.19</td>
<td>n/s</td>
<td>1583/4944</td>
<td>AS</td>
</tr>
<tr>
<td>rs560426 (G)</td>
<td>*</td>
<td>colorectal cancer</td>
<td>C</td>
<td>T</td>
<td>1.85 × 10^{-3}</td>
<td>1.06</td>
<td>allelic</td>
<td>12,620/15,110</td>
<td>EU</td>
</tr>
<tr>
<td>rs560426 (G)</td>
<td>*</td>
<td>lymphoma (DLBCL)</td>
<td>C</td>
<td>T</td>
<td>4.23 × 10^{-2}</td>
<td>1.12</td>
<td>allelic</td>
<td>256/747</td>
<td>EU</td>
</tr>
<tr>
<td>rs7078160 (A)</td>
<td>†</td>
<td>skin cancer (BCC)</td>
<td>G</td>
<td>A</td>
<td>1.62 × 10^{-3}</td>
<td>1.14</td>
<td>allelic</td>
<td>2807/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs7078160 (A)</td>
<td>*</td>
<td>brain cancer (glioma)</td>
<td>G</td>
<td>A</td>
<td>3.12 × 10^{-2}</td>
<td>1.16</td>
<td>n/s</td>
<td>1247/2236</td>
<td>EU*</td>
</tr>
<tr>
<td>rs7078160 (A)</td>
<td>*</td>
<td>skin cancer (CM)</td>
<td>G</td>
<td>A</td>
<td>3.15 × 10^{-2}</td>
<td>1.16</td>
<td>n/s</td>
<td>725/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs7632427 (C)</td>
<td>*</td>
<td>brain cancer (glioma)</td>
<td>C</td>
<td>T</td>
<td>1.46 × 10^{-2}</td>
<td>1.12</td>
<td>allelic</td>
<td>973/60,000</td>
<td>EU</td>
</tr>
<tr>
<td>rs7632427 (T)</td>
<td>†</td>
<td>brain cancer (glioma)</td>
<td>T</td>
<td>C</td>
<td>4.84 × 10^{-2}</td>
<td>1.10</td>
<td>additive</td>
<td>2331/3077</td>
<td>AS</td>
</tr>
<tr>
<td>rs816020 (A)</td>
<td>†</td>
<td>leukemia (ALL)</td>
<td>G</td>
<td>A</td>
<td>3.13 × 10^{-2}</td>
<td>1.28</td>
<td>n/s</td>
<td>1696/3535</td>
<td>EU</td>
</tr>
<tr>
<td>rs816020 (A)</td>
<td>*</td>
<td>lymphoma (FL)</td>
<td>G</td>
<td>A</td>
<td>4.97 × 10^{-2}</td>
<td>1.33</td>
<td>allelic</td>
<td>213/750</td>
<td>EU*</td>
</tr>
<tr>
<td>rs987525 (A)</td>
<td>*</td>
<td>lymphoma (GL)</td>
<td>G</td>
<td>A</td>
<td>1.15 × 10^{-3}</td>
<td>1.20</td>
<td>n/s</td>
<td>846/1310</td>
<td>EU*</td>
</tr>
<tr>
<td>rs987525 (A)</td>
<td>*</td>
<td>lymphoma (BCC)</td>
<td>G</td>
<td>A</td>
<td>3.65 × 10^{-2}</td>
<td>1.14</td>
<td>n/s</td>
<td>1423/1190</td>
<td>EU*</td>
</tr>
</tbody>
</table>

Risk = Risk allele in cancer GWAS; Ref = Reference allele in cancer GWAS; OR = Odds Ratio; * SNP genotyped; † SNP imputed; NO data available for SNP; SCC = squamous cell carcinoma; BCC = basal cell carcinoma; CM = cutaneous melanoma; CL = chronic lymphocytic leukemia; DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma; EU = European ethnicity; AS = Asian ethnicity; n/s = not specified.

* Association P-value from cancer GWAS.

**95% are known or assumed to be White and Not Hispanic.

† German subgroup.

‡ US subgroup.

§ French subgroup.
these SNPs, the “cancer risk allele” was identical to the “NSCL/P risk allele” (Table 2). For the cancer-associated SNP rs6457327 on chromosome 6p21.33, a borderline association was reported in the European NSCL/P dataset. However, this became non-significant following correction for multiple testing (\(P_{\text{adj}} = 0.0528\)). In the original report, the SNP rs6457327 was associated with follicular lymphoma [54]. In the original cancer GWAS, risk was conferred by the C allele at this SNP, which is identical to the risk allele in the NSCL/P meta-analyses dataset.

Analyses were then performed to identify associations with the lead SNPs of the 12 NSCL/P loci in 32 different cancer sample datasets. Eight SNPs achieved nominal significance in at least one sample dataset. The association of rs13041247 at chromosome 20q12 with squamous cell cancer of the skin \( (P_{\text{adj}} = 4.73 \times 10^{-6}) \) was significant after conservative Bonferroni correction for 384 tests. However, the risk allele for this SNP reported in squamous cell cancer of the skin differs from that found in the NSCL/P patients (Table 3).

Two CDH1 SNPs (rs9929218 and rs1862748) were included in the present study as they had shown genome-wide significant results in a GWAS of colorectal cancer [30]. The SNP rs1862748 showed nominal significance \( (P = 3.57 \times 10^{-2}) \) in the present NSCL/P dataset (Table 2).

The literature search for cancer risk SNPs identified 16 SNPs in the region of 8q24.21. This region also contains a key susceptibility locus for NSCL/P, with the top marker being rs987525. None of the cancer risk SNPs showed significant association in the NSCL/P datasets, and no association with rs987525 was found in any of the investigated cancer datasets (Table 4).

4. Discussion

The aim of the present study was to identify common genetic risk loci for NSCL/P and those cancer entities that have been reported to co-occur with NSCL/P in descriptive studies. Two approaches were used. First, conclusively identified cancer susceptibility variants were analyzed in a large genome-wide SNP dataset of NSCL/P patients. Second, known NSCL/P risk loci were analyzed in GWAS data for specific cancer entities. Analysis of only a subset of candidate SNPs, i.e., those identified as being genome-wide significant for one trait, reduced the number of tests and thus the requirement for correction, thereby increasing the chances of identifying common risk loci.

In principle, an overlapping genetic contribution to both traits could also be quantified using a genome-wide polygenic score approach [51]. However, for this etiological overlap to be apparent in a polygenic score, a specific cancer entity and NSCL/P would have to share a large number of genetic risk factors. Given the weak associations reported for cancer entities and NSCL/P in previous epidemiological studies, the presence of a large number of shared genetic risk factors cannot be assumed. In addition, since the polygenic score allows no conclusions to be drawn concerning a particular gene, this approach would allow no conclusions concerning a common biological pathway for NSCL/P and any specific cancer entity. We therefore considered the present methodology to be the more appropriate approach to our research question.

One association withstand correction for multiple testing. The NSCL/P-associated risk SNP rs13041247 at chromosome 20q12 showed genome-wide significant association in the dataset of the Icelandic cancer registry for squamous cell carcinoma of the skin. However, the NSCL/P risk allele \( (T) \) is not identical to the skin cancer risk allele \( (C) \). The SNP rs13041247 maps 45 kb downstream of the muscle-auxin-responsive fibrosarcoma oncogene homolog B \( (MAFB) \) gene, which encodes the \( \gamma\)-map transcription factor. In the GWAS of NSCL/P conducted by Beaty et al. [2], which was the first to describe association of this variant with NSCL/P, sequencing of conserved elements within the 3¢ region and the coding region of MAFB in NSCL/P cases and controls from Iowa and the Philippines revealed an overrepresentation of a rare missense variant \( \text{His131Gln} \). The contribution of this variant to NSCL/P was identified using the gene-based \( \text{Van der Woude syndrome} [50], which is the most common syndromic form of cleft lip and palate. Furthermore, Bhandari et al. [3] observed a marked reduction or absence of \( \text{GRLH3} \) expression in squamous cell skin carcinoma samples from mice and humans. A recent study identified dominant negative Klf4 variants in patients with NSCL/P [38].

Of the cancer-associated SNPs, the most significant \( P \)-value in the NSCL/P meta-analyses datasets was found for rs6457327 at 6p21.33, although this fell short of significance after correction for multiple testing. This SNP was originally reported by Skibola et al. [54] as a risk locus for follicular lymphoma, and maps 58 kb downstream of the POU class 5 homeobox 1 \( (POUSF1) \) gene, also known as \( \text{OCT4} \). This gene encodes a transcription factor with an important role in embryonic development, in particular during early embryogenesis, which is necessary for maintaining embryonic stem cell pluripotency [57]. Wang et al. [66]...
showed that OCT4 regulates and interacts with the BMP4 pathway in specifying different developmental fates in human embryonic stem cells. Notably, the BMP4 pathway is involved in mammalian palatogenesis [71], and mutations in BMP4 have been associated with human NSCL/P [12,58,59]. Research has shown that OCT4 is overexpressed in cancer cell lines and in diverse cancer entities [24,37,67], suggesting that aberrant transcriptional regulation of OCT4 is a mechanism in cancer susceptibility. Thus, a plausible hypothesis is that rs6457327 regulates OCT4 expression, and that this regulation is a possible common process in oncogenesis and the development of NSCL/P.

An important consideration in interpreting the present results is that the publication search adhered to very strict inclusion criteria, which might have introduced two sources of bias. First, we concentrated on investigating cancer risk association with NSCL/P and no other OEC subtype in order to reduce any existing genetic heterogeneity. However, as OEC nomenclature is applied inconsistently, we cannot exclude the possibility that our investigation included cancer entities that were associated with forms of OEC other than “pure” NSCL/P. Second, we may have rejected genuinely associated cancer entities due to a non-precise description of a possible association with NSCL/P. In the respective publication, Frebourg et al. [23] and Kluijt et al. [33] described a possible co-segregation of OEC and CDH1-related gastric cancer, and recent resequencing and association studies strongly support a contribution to NSCL/P of predominantly rare and moderately penetrant CDH1 variants [8]. As this co-occurrence was not precisely related to NSCL/P in the initial studies, and no other study of this cancer entity had been published by July 2012, gastric cancer was not included in the present cancer entity list. Nonetheless, two CDH1 SNPs (rs9620218 and rs1862748) were included, as they had shown genome-wide significant results in a GWAS of colorectal cancer [30], and rs1862748 showed nominal significance ($P = 3.57 \times 10^{-2}$) in the present NSCL/P dataset (Table 2).

Another important consideration is that most of the individuals investigated in the descriptive studies had a relatively low mean- and median age. Bille et al. [4] were the only authors to investigate the co-occurrence of OEC and cancer in adults (maximum age: 62 years). Consequently, the present analyses may have failed to consider cancers that are more frequent in later life.

In addition, we cannot exclude the possibility that NSCL/P is associated with cancer-subtypes other than those considered in the present study. Many of the GWAS concentrated on specific cancer subtypes. For example, studies of leukemia and lymphoma were conducted using case cohorts of acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, follicular lymphoma, and Hodgkin’s lymphoma (Supplementary Tables S2.4 and S2.6), which do not represent all forms of leukemia and lymphoma. This also applies to the skin cancer studies, since most of the GWAS of skin cancer were performed for the most frequent skin cancer subtypes, such as cutaneous melanoma, basal cell carcinoma, and squamous cell carcinoma.

An interesting result of the present study is the finding for the 8q24.21 region. This contains a key susceptibility locus for NSCL/P, and although it was initially identified in a small GWAS, the genetic effect was very pronounced [5]. The finding has since been confirmed in numerous GWAS and targeted replication studies [42]. The top marker, rs987525, maps to an intergenic region, which may contain remote cis-acting enhancers that control expression of the well known proto-oncogene Myc in the developing murine facial primordia [64]. Sixteen of the present cancer-risk SNPs are located in the 8q24.21 region (Table 4). However, none of these SNPs showed a statistically significant association in the NSCL/P data-sets. Furthermore, none of these cancer risk variants is in linkage disequilibrium with rs987525, which suggests that this locus might contain distinct regulatory regions that are responsible for different developmental processes. This hypothesis is supported by data from Ushl et al. [64], who showed that a distinct region adjacent to rs987525 contained a specific facial enhancer element. Deletion of this medial-nasal enhancer resulted in a pronounced reduction in myc expression in the facial tissues of homozygous murine embryos but not in other embryonic tissues. Therefore it is possible that the 8q24 region contains enhancers that control the expression of Myc in either facial development or cancer but not in both.

In summary, the present study is the first to characterize possible pleiotropic risk loci for NSCL/P and cancer using large genome-wide datasets. Suggestive evidence for a common genetic background was found for NSCL/P and follicular lymphoma at 6p21.33, and for NSCL/P and squamous cell carcinoma of the skin at 20q12. Whether, and to what extent, the development of these phenotypes is influenced by an altered function of the putative candidate genes OCT4 and MAFA at these loci remains unclear. No marker in the present study showed pronounced effects on both phenotypes. Although inconclusive at the single marker level, the present data represent a starting point for further research into the common genetic etiology of OEC and cancer.

**Conflicts of interest**

None

**GECCO funding**

GECCO: National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (U01 CA137088; R01 CA059045).

ASTERISK: a Hospital Clinical Research Program (PHRC) and supported by the Regional Council of Pays de la Loire, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne Génétique and the Ligue Régionale Contre le Cancer (LRCC).

COLO283: National Institutes of Health (R01 CA60987).

CCFR: This work was supported by grant U1M CA167551 from the National Cancer Institute and through cooperative agreements with the following CCFR centers:

- Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24 CA097735).
- Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01/U24 CA074800).
- Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783).
- Seattle Colorectal Cancer Family Registry (U01/U24 CA074794).
- University of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806).
- U.S. Consortium Colorectal Cancer Family Registry (U01/U24 CA074799).

The Colon CFR GWAS was supported by funding from the National Cancer Institute, National Institutes of Health (U01 CA122839 and R01 CA143237 to Graham Casey). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR.

DACHS: German Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4 and CH 117/1-1), and the German Federal Ministry of Education and Research (01KHO404 and 01ER0814).

DALS: National Institutes of Health (R01 CA48998 to M. L. Slattery); HPPS is supported by the National Institutes of Health (P01 CA 05075, UM1 CA167552, R01 137178, R01 CA151993 and P50 CA127003), NHS by the National Institutes of Health (UM1 CA186107, R01 CA137178, P01 CA87969, R01 CA151993 and P50 CA127003,) and PHS by the National Institutes of Health (R01 CA642182).

MEC: National Institutes of Health (R37 CA54281, P01 CA033619, and R01 CA63464).

OFCCR: National Institutes of Health, through funding allocated to the Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783); see CCFR section above. Additional funding toward genetic
analyses of OFCCR includes the Ontario Research Fund, the Canadian Institutes of Health Research, and the Ontario Institute for Cancer Research, through generous support from the Ontario Ministry of Research and Innovation.

PLCO: Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DPHS. Additionally, a subset of control samples were genotyped as part of the Cancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer GWAS (Yeger, M et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007 May;39(5):645-9), Colon CGEMS pancreatic cancer scan (PanScan) (Amundadottir, L et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009 Sep;41(9):986-90, and Petersen, GM et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q12.1, 1q32.1 and 5p15.33. Nat Genet. 2010 Mar;42(3):224-8), and the Lung Cancer and Smoking study (Landi MT, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009 Nov;85(5):679-91). The prostate and PanScan datasets were accessed from the dbGaP website (http://www.ncbi.nlm.nih.gov/gap) through accession numbers phs000093.v2.p2, respectively, and the lung datasets were accessed from the dbGaP website (http://www.ncbi.nlm.nih.gov/gap) through accession number phs000093.v2.p2. Funding for the Lung Cancer and Smoking study was provided by National Institutes of Health (NIH), Genes, Environment and Health Initiative (GEI) Z01 CP 010200, NIH U01 HG004446, and NIH GEI U01 HG 004438. For the lung study, the GENEVA Coordinating Center provided assistance with genotype cleaning and general study coordination, and the Johns Hopkins University Center for Inherited Disease Research conducted genotyping.

PMH: National Institutes of Health (R01 CA076366 to P.A. Newcomb).

VITAL: National Institutes of Health (K05 CA154337).

WHI: The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, and HHSN268201100004C, and HHSN271201100004C.

Acknowledgements

We thank all affected individuals and their families for their participation in this study, as well as the German support group for persons with cleft lip and/or palate (Deutsche Selbsthilfegruppe für Lippen-Gaumen-Fehlbildungen e.V.). The study was supported by the Deutsche Forschungsgemeinschaft (FOR 423 and individual grants MA 2546/3-1, KR 1912/7-1, NO 246/6-1 and WI 1555/5-1). In particular, we thank the following researchers for the provision of data: deCODE Genetics (Reykjavik, Iceland); Victor Enciso (The Institute of Cancer Research, Sutton, Surrey, UK); Susan L. Slager (Mayo Clinic, Rochester, MN, USA); and Peter Kraft (Harvard School of Public Health, Boston, MA, USA). The study was also supported by Richard S. Houlston (The Institute of Cancer Research, Sutton, Surrey, UK); Noralane M. Lindor (Mayo Clinic, Department of Health Sciences Research, Mayo Clinic Arizona, USA); and Zhibin Hu and Hongbing Shen of Nanjing Medical University.

Christine F Skibola was supported by the National Institutes of Health R01CA1046282 and R01CA154643.

Ping Yang received support from grants NCI-CA77118 and CA80127, and from the Mayo Foundation.

Hidewaki Nakagawa was supported by BioBank Japan.

Jong-Won Kim was supported by the Korean Health Technology R&D Project (A120030).

The Environment and Genetics in Lung Cancer Etiology (EAGLE), Prostate, Lung, Colon, Ovary Screening Trial (PLCO), and Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) studies were supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics. ATBC was also supported by U.S. Public Health Service contracts (N01-CN-45165, N01-RC-45035, and N01-RC-37040) from the NCI. PLCO was also supported by individual contracts from the NCI to the University of Colorado Denver (N01-CN-25514), Georgetown University (N01-CN-25522), the Pacific Health Research Institute (N01-CN-25515), the Henry Ford Health System (N01-CN-25512), the University of Minnesota, (N01-CN-25513), Washington University (N01-CN-25516), the University of Pittsburgh (N01-CN-25511), the University of Utah (N01-CN-25524), the Marshfield Clinic Research Foundation (N01-CN-25518), the University of Alabama at Birmingham (N01-CN-75022), Westat, Inc. (N01-CN-25476), and the University of California, Los Angeles (N01-CN-25404). The Cancer Prevention Study-II (CPS-II) Nutrition Cohort was supported by the American Cancer Society. The NIH Genes, Environment and Health Initiative (GEI) partly funded DNA extraction and statistical analyses (HG-06-033-
Appendix A. Supplementary data

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.gdata.2016.08.017.

References


